Department of Medical Oncology, Faculty of Medicine, Trakya University, Edirne, Turkey.
Eur Radiol. 2014 Jan;24(1):184-90. doi: 10.1007/s00330-013-2996-6. Epub 2013 Sep 25.
To determine the frequency of and possible factors related to contrast-induced nephropathy (CIN) in hospitalised patients with cancer.
Ninety adult patients were enrolled. Patients with risk factors for acute renal failure were excluded. Blood samples were examined the day before contrast-enhanced computed tomography (CT) and serially for 3 days thereafter. CIN was defined as an increase in serum creatinine (Cr) of 0.5 mg/dl or more, or elevation of Cr to 25 % over baseline. Relationships between CIN and possible risk factors were investigated.
CIN was detected in 18/90 (20 %) patients. CIN developed in 25.5 % patients who underwent chemotherapy and in 11 % patients who did not (P = 0.1). CIN more frequently developed in patients who had undergone CT within 45 days after the last chemotherapy (P = 0.005); it was also an independent risk factor (P = 0.017). CIN was significantly more after treatment with bevacizumab/irinotecan (P = 0.021) and in patients with hypertension (P = 0.044).
The incidence of CIN after CT in hospitalised oncological patients was 20 %. CIN developed 4.5-times more frequently in patients with cancer who had undergone recent chemotherapy. Hypertension and the combination of bevacizumab/irinotecan may be additional risk factors for CIN development.
• Contrast-induced nephropathy (CIN) is a concern for oncological patients undergoing CT. • CIN occurs more often when CT is performed <45 days after chemotherapy. • Hypertension and treatment with bevacizumab appear to be additional risk factors.
确定癌症住院患者中对比剂肾病（CIN）的发生频率及相关因素。
共纳入 90 例成年患者。排除有急性肾衰竭风险的患者。在增强 CT 检查前一天和之后连续 3 天检查血样。CIN 定义为血清肌酐（Cr）升高 0.5mg/dl 或以上，或 Cr 升高至基线的 25%以上。研究了 CIN 与可能的危险因素之间的关系。
在 90 例患者中，18 例（20%）发生 CIN。接受化疗的患者中 25.5%发生 CIN，未接受化疗的患者中 11%发生 CIN（P=0.1）。在最后一次化疗后 45 天内接受 CT 的患者中，CIN 更常发生（P=0.005）；这也是一个独立的危险因素（P=0.017）。与贝伐珠单抗/伊立替康（P=0.021）治疗和高血压（P=0.044）相关的 CIN 发生率更高。
在接受 CT 的癌症住院患者中，CIN 的发生率为 20%。最近接受化疗的癌症患者发生 CIN 的风险增加 4.5 倍。高血压和贝伐珠单抗/伊立替康联合治疗可能是 CIN 发生的其他危险因素。
• CT 检查的癌症患者会出现对比剂肾病（CIN）。
• CT 检查在化疗后 <45 天内进行时，CIN 更常见。
• 高血压和贝伐珠单抗治疗似乎是其他危险因素。
